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Background 
Honey has been used as a traditional folk medicine since ancient times, both 
externally on wounds to the epidermis and internally for respiratory and 
gastrointestinal tract infections (Mandal et al., 2010; Lusby et al., 2005; Kwakman et 
al., 2010; Ayaad et al., 2010). Honey has a proven anti-microbial effect, and due to 
an increasing level of bacterial resistance to antibiotics, new research is looking into 
the clinical application of honey as an alternative to conventional antibiotics. Most 
research analyses honey for application as a wound dressing, as it has several 
mechanisms that aid in the healing process other than an anti-bacterial activity. For 
example honey maintains a moist wound environment for healing, whilst offering a 
protective barrier via its high osmolarity; in addition the mild acidity and hydrogen 
peroxide release support tissue repair (Mandal et al., 2010; Lusby et al., 2005). 
Whilst honey has proven efficient as a bactericidal and bacteriostatic agent in vitro 
and in case studies, the mechanism by which honey exerts this activity, against a 
broad spectrum of organisms, is still under debate. The high osmolarity and 
hydrogen peroxide content are often cited as likely contributors; however, when a 
sugar solution is made to the same osmolarity as the honey in question, it has a 
notably smaller effect on bacteria. In addition some honeys have been found to have 
a non-peroxide affect, the most well-known case being Manuka honey (Kwakman et 
al., 2010; Snow and Manley-Harris, 2004). Other components of interest are 
phytochemicals, pH, methyglyoxal (MGO) and bee defensin-1(Kwakman et al., 2010).  
As honey is a natural product, its content is highly variable and will change with floral 
source, location and bee species, therefore it is difficult to standardise honeys and 
assess their usefulness in a medical setting. Honey can be used clinically if it is a 
medical grade product, i.e. a sterilised product that is licensed for use (Molan, 2006). 
Two medical grade honeys are Revamil source (RS) honey, and Manuka, i.e. 
Medihoney (Majtan, 2011); RS honey is produced under controlled conditions in 
greenhouses (thus having a reproducible anti-bacterial activity), and Manuka is 
assessed for a Unique Manuka Factor (UMF), in which the batch is given a number 
based on its bactericidal activity (Kwakman et al., 2010; Kwakman et al., 2011). The 
use of honey in a medical setting would not only be helpful in combating bacterial 
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resistance (there is no evidence to suggest bacteria develop resistance to honey), 
but aid the treatment of infections in developing countries, as honey is cheap, easily 
available and may avert the need for other more expensive medical treatments. 
Moghazy et al. (2010) also suggested after their in vivo experiment in Egypt that due 
to its long standing use as a remedy in certain countries, it may have a psychological 
benefit over other treatments.  
Components of interest in honey 
Hydrogen peroxide (H2O2) is one of the main elements of honey considered when 
looking into antibacterial activity. Its production is the result of the enzyme glucose 
oxidase produced by bees; this enzyme uses glucose and oxygen to create gluconic 
acid and H2O2, and is activated when honey is diluted (Tonks et al., 2001). Glucose 
oxidase is affected by heat and light and is inhibited by catalase. Catalase can be 
present in flower pollen and in the tissues of the body (Mandal and Mandal, 2011). 
Sherlock et al. (2010) have speculated that the presence of catalase in wound tissue 
may have an inhibitory effect on hydrogen peroxide production by honey, making 
non-peroxide activity an important factor in a clinical setting. Some honeys exhibit 
activity in the presence of catalase that cannot be explained solely by their high 
sugar content. Many honeys are kept in the dark and at room temperature prior to 
experimentation to prevent the degradation of glucose oxidase and the loss of 
hydrogen peroxide (Sherlock et al., 2010). 
High osmolarity is also considered an important factor as it inhibits bacterial growth 
by drawing moisture from the environment and dehydrating the micro-organisms 
(Mandal and Mandal, 2011). This means that an artificial honey made to the same 
concentration of sugar (~80% w/v [Kwakman et al., 2010]) as real honey does exhibit 
some antibacterial activity, but this is often lower than that of the honeys it is being 
compared to.  
pH is a likely factor in undiluted honey, as most honeys are naturally acidic (pH3.2-
4.5) and this will inhibit the activity of many micro-organisms (Mandal and Mandal, 
2011). When honey is diluted this pH changes and may become more neutral, but 
activity is still observed, so it is not thought to be a central factor.  
Methylglyoxal (MGO) is a protein-glycating agent and has been found in medical 
honeys and is thought to be responsible for the non-peroxide activity observed in 
some honeys (Badet and Quero, 2011; Majtan, 2011). Its activity in diabetic ulcers 
has been questioned on the grounds of safety issues, due to the production of 
advanced glycation end products; which cause health complications in diabetes 
(Majtan, 2011). 
Bee Defensin-1 was found in Revamil honey by Kwakman et al., (2010) and was 
shown to contribute towards the anti-bacterial activity against some bacterial species. 
Propolis is a resinous structural component of the hive composed of floral elements, 
such as tree sap. It can have anti-microbial activity which some honeys may be 
exposed to it (Boorn et al., 2009). 
The honey’s micro flora has been implied in the activity of honey; Lee et al., (2008) 
tested bacterial isolates from American honeys and manuka to determine if they 
produced anti-microbial agents, and found that a majority did, with one of the 
manuka samples having the highest isolate activity.  
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Kwakman et al., (2010) gradually removed/inhibited the MGO, H2O2, bee defensin-
1and altered pH to see what was responsible for the broad spectrum antibacterial 
activity, in Revamil. They found that different bacteria were sensitive to different 
components, e.g. the neutralisation of MGO alone reduced the activity against 
Escherichia coli and Pseudomonas aeruginosa, and the neutralisation of H2O2 
reduced activity against all tested organisms accept Bacillus subtilis. When MGO, 
H2O2, and Bee defensin-1 activity were removed, and the pH was adjusted to pH7, 
the honey had the same activity as the artificial honey. The concentration of each of 
these components and any other factors involved will vary with each honey due to 
different floral sources, bee colonies, season, etc. (Sherlock et al., 2010) 
Types of honey 
Manuka is perhaps the most well characterised honey in anti-microbial exeriments, 
with many papers using it as a postive control based on its proven activity. Produced 
in New Zealand, Manuka honey is formed from nectar of the manuka bush 
(Leptopsermum scoparium) and is well known for its non-peroxide effect, as well as 
its anti-microbial potency. A UMF is given to each batch of Manuka honey to rate its 
anti-bacterial nature. This number is based on  the comparison of the honey’s 
activity, in a standard laboratory test, against that of phenol (a potent  anti-septic); 
based on this a UMF of 10 would be equivalent to 10% phenol activity (Badet and 
Quero, 2011). Weston (2000) suggested that the experiments which had shown non-
peroxide activity in manuka had not used sufficient catalase to destroy its activity, as 
it is continuously created during the testing process and is the only anti-bacterial 
compound of significance in honey. Snow and Manley-Harris (2003) tested this 
theory by performing a well diffusion assay with a 10-fold excess of catalase, and 
disovered that the activity of the honey treated with catalase was equal to that of un-
treated manuka, strongly suggesting that manuka does it indeed act via a hydrogen 
peroxide independent mechanism. Other studies have tried to determine what then 
is responsible for manuka’s activity and the question still remains open, though 
several options have been put forward. Bogdanov (1997) discovered when filtering 
the honey on an anion exchange column  at pH 11 that all activity was irreversibly 
lost, and therefore concluded the activity was in the acidic fraction. Snow and 
Manley-Harris (2003) also tested this by altering the honey’s pH (without 
chromatography) and found that at pH 9 activity became un-stable, and at pH11 the 
activity was lost immediatly and did not return when the pH was adjusted back to pH 
7. Methylglyoxal (MGO) is derived from dihydroxyacetone, which can be found at 
high levels in nectar from the Manuka bush (Irish et al., 2011). MGO has been found 
at high levels in Manuka honey and is thought to be the cause of its non-peroxide 
activity; anti-bacterial activty is reduced in RS honey when MGO is neutralised 
(Kwakman et al., 2010), showing that MGO does have anti-bacterial activity. The 
non-peroxide activity of Manuka is important clinically,firstly because it is not affected 
by the body’s own catalase, but also because Manuka can be sterilised by γ-
irraditation without losing its activity (Irish et al., 2011).  
Ulmo honey is produced in Chile and was investigated by Sherlock et al. (2010) to 
determine if its activity was comparable to the of Manuka honey; this was done on 
the grounds that local honeys should be assessed, as there are more easily 
available. Manuka UMF25+ was used in comparison to Ulmo 90, with the Ulmo tree 
(Eucryphia cordifolia) being the source of nectar for 90% of the Ulmo honey. The test 
bacteria used were E.coli, P.aeruginosa and 5 strains of methicillin-resistant 
Staphylococcus aureus (MRSA). Using agar well diffusion and two-fold dilutions from 
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50% down to 0.02%, the minimum inhibitory concentration (MIC) for each 
bacteria/honey combination was assessed. The results showed that Ulmo had 
results that were indistinguishable from Manuka, for E.coli and P.aeruginosa, 
however MRSA was found to be more (or equally) sensitive to Ulmo 90 than Manuka; 
with the Ulmo 90 MIC being 3.1-6.3% v/v compared to Manuka’s 12.5%, while 
artificial honey had a 50% MIC for all bacteria. However, when catalase treatment 
was used, Ulmo 90 lost its activity at 25%, but Manuka maintained its activity. They 
therefore concluded that Ulmo 90 has peroxide dependent anti-bacterial activity that 
is greater than Manuka against 5 strains of MRSA. They do however point out that 
catalase may be present in the wound environment, as it is endogenous to tissue; 
also the bacterial composition of a wound is different to that seen in tests on 
planktonic bacteria, as the wound will contain a biofilm of several bacteria which may 
affect the ability of honey to kill or inhibit the organisms present.  
Tualang Honey is local to Malaysia and its floral origin isn’t yet known; its 
antibacterial activity was tested by Tze Tan et al. (2009) against wound and enteric 
micro-organisms (5 Gram-positive bacteria and 8 Gram-negative). Again Manuka 
was used as a comparison, this time with a UMF10+. Both honeys were γ-irradiated 
to kill any micro-organisms present in the honey; this treatment has been shown not 
to affect the activities of these honeys. MIC was determined by broth dilution and 
measuring optical density at 620nm, the non-peroxide activity however was 
determined via agar well diffusion. The MIC values for both honeys was between 10-
25% on the 13 bacteria tested, putting Tualang’s activity in the same range as that of 
Manuka’s; Tualang also maintained its activity after catalase treatment, suggesting it 
has non-peroxide activity. Tze Tan et al. (2009) concluded that although Tualang 
activity was variable amongst the 13 bacteria, its potency against some of the micro-
organisms gives it potential as an alternative to antibiotics. 
Revamil (RS) honey is a medical grade honey created under control conditions in 
green houses. Kwakman et al. (2010) found that its broad spectrum activity is down 
to hydrogen peroxide, MGO and bee defensin-1. When comparing the time and 
dilutions needed to kill bacteria, it was found that RS honey killed most organisms in 
a more rapid manner than Manuka, but was comparatively less effective at lower 
concentrations (Kwakman et al., 2011). 
Types of Bee 
Boorn et al. (2009) observed that a majority of research was done on honey 
produced by the bee Apis mellifera, and therefore examined the differences between 
these honeys and honey produced by the stingless bee Trigona carbonaria from 
Australia. 11 stingless bee honey samples were used, with a combination of plants 
as the floral source; comparison honeys consisted of medical, table and artificial 
honey. Boorn et al. (2009) used several methods to determine the anti-microbial 
activity, as conflicting results have been observed in the past relating to this bee. 
Large differences were found between the 11 samples, but the honey did exhibit 
broad spectrum anti-bacterial activity comparable to medical grade honey, with the 
time-kill assay suggesting it had quicker activity; it was however ineffective at killing 
fungi. There are many differences between stingless bee honey and Apis; one of 
interest is the different storage methods within the hive. Stingless bee honey is kept 
in pots made of propolis and wax rather than combs made solely of wax, giving the 
honey a greater chance of being imbued with plant-derived anti-microbial agents. 
Irish et al. (2011) also suggested that different bee colonies could affect the activity 
The Plymouth Student Scientist, 2013, 6, (1), 376-385 
  
[380] 
 
of the honey, as when testing floral sources for effects on activity, they found 
difference between honeys from the same floral source but different hives could vary 
widely in their activity against S.aureus. This could perhaps explain the differences 
between Manuka honey’s as they can vary in potency from 10-25+ UMF.  
Different floral sources and other factors that may influence activity 
The differences between honeys are usually attributed to their different floral sources. 
Irish et al. (2011) sought to determine the activity of different honeys from various 
Australian floral sources by using an agar well diffusion method against S.aureus. 
477 samples were collected and 57% showed activity greater than or equal to 10% 
phenol; 80 of these 477 samples showed non-peroxide activity and Leptospermum 
spp was the main or sole source of 77.5% of these honeys.  However Australian L. 
scoparium (the Manuka bush) samples did not show non-peroxide activity, as it does 
in New Zealand; suggesting that other, as yet unidentified factors (such as 
environmental factors) contribute to the non-peroxide activity of New Zealand 
Manuka honey.  
Lee et al. (2008) compared the antimicrobial activity of American honeys and 
Manuka; they found that American honeys exhibited lower activity. The majority of 
samples contained hydrogen peroxide and some were affected by proteolytic 
enzymes (Manuka was not), suggesting that active proteins and peptides play a part 
in their activity. Lee et al. (2008) also found bacterial isolates, in the American and 
Manuka honey, which exhibited antimicrobial properties that contribute to the activity 
observed. 
The storage conditions and age of the honey samples were also considered in the 
Irish et al. (2011) study. While the age of the honeys (8 and 22 months) did not 
correlate with activity, storage at 4°C and 25°C resulted in loss of peroxide activity, 
with a greater loss seen at 25°C; an optimal storage temperature was not suggested. 
Temperature was also found to affect the activity of honey in Mulu et al.’s (2004) 
study, in which honey produced by Apis mellifera was used. They found that 
although honey was unaffected by storage at -10°C, the minimal bactericidal 
concentration (MBC) decreased by 1.2% following autoclaving (121°C) for 15 
minutes. They concluded that autoclaving would have stopped the activity of the 
heat-liable phytochemicals, as well as enzymes such as glucose oxidase; this has 
implications in the results of other studies that have used autoclaving as a means of 
sterilisation, such as Mandal et al. (2010) who studied honey from west Bengal. 
Clinical studies on Honey’s activity in wound treatment 
There have been many randomised and clinical trials on the use of honey in the 
treatment of wounds, with several producing favourable results; however many are 
criticised as being of low-quality due to lack of double-blinding (Moore et al., 2001; 
Molan, 2006). Molan (2006) argues however, that blinding is next to impossible to do, 
due to the very recognisable look and aroma of honey; however there is evidence to 
suggest the activity is not a result of the placebo effect. For example, multiple wound 
patients have been tested with honey and a comparative treatment simultaneously, 
and honey was shown to be significantly better; animal studies also show a positive 
result for honey without the influence of psychological belief (Molan, 2006).  
The majority of evidence that supports the use of honey is where honey dressings 
were applied to partial thickness or mild to moderate superficial burns, while 
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evidence for benefits on ulcers has been contradictory (Majtan, 2011). Hyperosmolar 
sugar paste has proven to be effective in animal experiments, and to be superior to 
antiseptics; it explains some of the benefits seen when honey is used (Moore et al., 
2001). When honey is compared to other treatments, Moore et al. (2001) found that 
of 7 randomised trials examined, 6 reported honey as being superior to other 
treatments (both conventional and alternative). But it was concluded that the 
evidence was of such low quality that caution should be taken when interpreting the 
results. Molan (2006) on the other hand, advises clinicians to consider the wide 
range of evidence supporting the use of honey; as many modern wound dressings 
have equally low quality evidence, and there may not be as many studies e.g. 
nanocrystalline silver dressing. When Molan (2006) investigated trials using honey, 
he found 17 randomised and 5 clinical trials (totalling more than 2060 participants) 
reported positive results when honey was used as a wound dressing.  
There is also a vast amount of in vitro evidence supporting both honey’s anti-
bacterial activity (see Table 1) and its immunomodulatory roles in promoting healing.  
 
Table 1: Summaries from a sample of studies that have found honey to have an 
antimicrobial activity in vitro. Minimum inhibitory concentration (MIC), Minimum bactericidal 
concentration (MBC). 
Authors Honey/s Micro-
organisms 
Method Results/conclusions 
Cursons, 
2010 
Manuka 
(equivalent to 
16.5% phenol) 
Gram negative 
bacteria 
Time-kill assay, 
with viable count 
measured hourly. 
Concentrations 
from 20% down. 
Manuka was better 
than artificial honey 
and acted in a 
bactericidal manner. 
20% killed most of the 
organisms between 2-
6 hours after onset. 
Most organisms were 
inhibited at 
concentration <8% 
v/v.  
Concluded that 
different organisms 
have different 
susceptibility to the 
effects of Manuka. 
 
Lusby et al., 
2005 
Local honeys 
(lavender, red 
stringy bark 
and 
Paterson’s 
curse) vs. 
Commercial 
honeys 
(Manuka, 
Rewa rewa 
and 
Medihoney). 
Used 13 
bacterial 
organisms 
(gram positive 
and gram 
negative) and 
1yeast.  
Agar dilution 
assay; 
concentrations of 
0.1%, 1%, 5%, 
10% and 20% w/v. 
The amount of 
inhibition observed 
increased with 
concentration, with 
most showing 75% 
inhibition at 20%. The 
local honeys were 
equivalent in activity 
to Manuka against 
some bacteria. 
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Badet and 
Quero, 2011 
Manuka UMF 
30+ and UMF 
16+ 
Oral bacteria Macro broth 
dilution for MICs 
and MBCs.  
UMF 30+ always had 
better activity than 
UMF 16+. The MBC 
was always at least 
two times the MIC. 
Both UMF’s inhibited 
adherence at levels 
below their MIC. 
Concluded that the 
anti-cariogenic effect 
of Manuka may 
counteract its high 
sugar content in oral 
health. 
 
Sherlock et 
al., 2010 
Ulmo 90 and 
Manuka UMF 
25+ 
5 clinical 
isolates of 
MRSA, E.coli 
and 
P.aeruginosa. 
Agar well diffusion 
assay using two-
fold dilutions 
beginning at 50%. 
Used a 
spectrophotometer 
to assess MIC. 
Catalase used. 
Ulmo and Manuka 
had similar effects on 
E.coli and 
P.aeruginosa. 
However some of the 
MRSA isolates were 
more sensitive to 
Ulmo. 
Catalase effected 
Ulmo activity and not 
Manuka. 
 
Mandal et al., 
2010 
Honey from 
west Bengal. 
E.coli, 
P.aeruginosa 
and 
Samonella 
enterica 
serotype 
Typhi. 
Agar dilution 
assay; 0.25%-4% 
v/v concentrations. 
Honey was 
autoclaved. 
MIC against: 
P.aeruginosa 3.5% 
v/v 
E.coli 3-3.5% v/v 
S.enterica 1.75-3% 
v/v 
Boorn et al., 
2009 
Stingless bee 
honey 
(Australia), 
Medical, 
artificial and 
table honey. 
Gram positive 
and gram 
negative 
bacteria, and 
fungi.  
Agar dilution 
assay, broth 
microdilution 
assay, agar 
diffusion assay 
and time-kill 
assay. 
Agar dilution MIC:  
4->10% w/v for gram 
positive 
6- >16% w/v for gram 
negative. 
6- >10% w/v for fungi. 
Concluded that 
stingless bee honey 
has a similar activity 
to medical honey. 
 
 
Tonks et al. (2001) studied the effects of Manuka and pasture honey (alongside an 
artificial control) on monocytes (Mono Mac 6 cells –MM6) and found that honey had 
both inhibitory and stimulatory activity on these cells. Reactive oxygen intermediates’ 
(ROIs) production was inhibited by both honeys, but more so by pasture honey, and 
it is suggested this is due to its higher hydrogen peroxide content. TNF-α production 
was stimulated in resting monocytes, but not in the primed ones; TNF-α is known to 
be beneficial in healing processes, and ROIs are part of macrophage mediated 
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damage, thus these two activities may be behind the healing properties associated 
with honey. 
Internal use 
Honey is a traditional remedy for sore throats, but there is very little evidence 
investigating the effects of honey in vivo on upper respiratory tract (URT) pathogens, 
and no in vitro studies were found that selected micro-organisms based on their 
ability to infect the URT, although some studies contained these kinds of pathogens.  
Two clinical studies which look at honey’s abilities when taken internally are: firstly, 
Paul et al. (2007), who investigated the effect of honey on nocturnal coughing and 
sleep quality in children. They found that honey was significantly better than no 
treatment, but not significantly different from Dextromethorphan treatment, for the 
reduction in cough frequency and improved sleep. However, Oduwole at al. (2010) 
concluded, when they reviewed data on whether honey could be used to treat 
coughs in children, that there was inadequate evidence to support the use of honey; 
but neither was there evidence to suggest it shouldn’t be used. Secondly, a study in 
Iran on the effect of honey on the common cold (Pourahmad and Sobhanian, 2008) 
found that out of the two groups, those receiving honey as well as conventional 
treatment had a smaller duration of signs and symptoms (1-2 days less) than those 
only receiving conventional treatment. They concluded that this is evidence that 
honey should be considered in more depth for the treatment of colds. 
Conclusion 
Honey is increasingly becoming a substance of interest, not only due to its 
sometimes potent activity against bacteria in vitro; but also due to promising results 
in vivo, where it also seems to promote healing, as well as sanitising the wound. 
Although there is still some question over its use, due to the low quality of the 
evidence produced by trials, because of the difficulty of blinding. However 
considering the increased rate of bacterial resistance being seen to antibiotics, and 
the expense of these drugs to non-industrial countries, it is worthy of consideration, 
as it addresses these problems. It is however clear that more clinical trials should be 
done using those honeys that having proven potent in vitro as a medical dressing, 
and on different wounds. As many honeys have shown activity against MRSA (e.g. 
Manuka and Ulmo), it would be interesting to see studies done using them as a 
dressing on MRSA abscesses in hospitals. Alongside this, other untested honeys 
should be assessed in vitro to determine if they have equivalent or better activity 
than those that have proven activity (i.e. Manuka).  
Further studies should also be considered on the effects of ingested honey on 
infections of the URT and gastrointestinal tract.  
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